Edwards Lifesciences Corporation ($EW) Stock Forecast: Up 0.6% Today

What is Edwards Lifesciences Corporation?

Edwards Lifesciences (NYSE: EW) is a medical technology company specializing in heart valves and hemodynamic monitoring. The company is known for its innovative products in the healthcare industry.

Why is Edwards Lifesciences Corporation going up?

EW stock is up 0.6% on Oct 31, 2025 14:40

• The bullish movement in Edwards Lifesciences (EW) stock today can be attributed to:
• Positive analyst upgrades indicating a favorable outlook on the company's performance.
• Anticipation and optimism surrounding the upcoming Q3 earnings report, with analysts projecting strong results.
• The news of an investigation by a law firm may have had a minimal impact on the market movement, as investors focused more on the positive analyst upgrades and earnings projections.

EW Price Chart

EW Technical Analysis

EW News

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Edwards Lifesciences ( NYSE:EW ) , Brookfield Infr Partners ( NYSE:BIP )

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

https://www.benzinga.com/analyst-stock-ratings/upgrades/25/10/48489404/this-edwards-lifesciences-analyst-turns-bullish-here-are-top-4-upgrades-for-wednes

Exploring Analyst Estimates for Edwards Lifesciences ( EW ) Q3 Earnings, Beyond Revenue and EPS

Besides Wall Street's top-and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.

https://www.zacks.com/stock/news/2778802/exploring-analyst-estimates-for-edwards-lifesciences-ew-q3-earnings-beyond-revenue-and-eps

EW Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW

New York, New York-- ( Newsfile Corp. - October 23, 2025 ) - Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation ( NYSE: EW ) .

https://markets.businessinsider.com/news/stocks/ew-investor-news-rosen-law-firm-announces-investigation-of-breaches-of-fiduciary-duties-by-the-directors-and-officers-of-edwards-lifesciences-corporation-ew-1035404256

Trending Today

ON Semiconductor Corporation ($ON) Stock Forecast: Up 3.2% Today

GitLab Inc. ($GTLB) Stock Forecast: Down 2.3% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Down 5.5% Today

Tapestry Inc. ($TPR) Stock Forecast: Down 3.0% Today

HP Inc. ($HPQ) Stock Forecast: Down 3.0% Today

Ethereum ($ETH) Crypto Forecast: Down 6.2% Today

IDEXX Laboratories Inc. ($IDXX) Stock Forecast: Up 1.5% Today

Workday Inc. ($WDAY) Stock Forecast: Down 3.2% Today

Fortinet Inc. ($FTNT) Stock Forecast: Down 1.9% Today

Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Down 2.4% Today

Edwards Lifesciences Corporation Price History

31.09.2025 - EW Stock was up 0.6%

• The bullish movement in Edwards Lifesciences (EW) stock today can be attributed to:
• Positive analyst upgrades indicating a favorable outlook on the company's performance.
• Anticipation and optimism surrounding the upcoming Q3 earnings report, with analysts projecting strong results.
• The news of an investigation by a law firm may have had a minimal impact on the market movement, as investors focused more on the positive analyst upgrades and earnings projections.

28.09.2025 - EW Stock was up 7.2%

• The optimistic movement in EW stock can be linked to favorable analyst estimates for its Q3 earnings, indicating strong performance and potential growth outlook.
• Despite ongoing investigations into potential breaches of fiduciary duties by EW's directors and officers, investors maintain a positive outlook on the company's future, influencing the bullish market trend.
• Investor confidence appears to be driven by the company's solid fundamentals and growth prospects rather than the legal scrutiny, resulting in the upward movement of the stock price.

24.03.2025 - EW Stock was up 7.2%

• Strong bullish movement in the stock today.
• Analysts upgraded the stock as the growth outlook brightened, with Q1 sales rising 58% YoY and beating consensus estimates.
• Q1 earnings and revenues surpassed expectations, leading to a raised sales view for 2025.
• The market responded positively to the company's performance and optimistic outlook, driving the stock price higher.

24.03.2025 - EW Stock was up 5.0%

• Q1 earnings and revenues of Edwards Lifesciences (EW) surpassed expectations, resulting in a surge in the stock price.
• The company's unique portfolio of therapies likely played a role in its strong market performance.
• An increased sales outlook for 2025 reflects positive market sentiment and confidence in the company's future growth.
• Analysts are delving into various key metrics beyond standard estimates, indicating a profound understanding of Edwards Lifesciences' potential for sustained success.

25.06.2025 - EW Stock was up 3.9%

• Edwards Lifesciences (EW) saw a significant uptrend in the market today.
• This rise is linked to the company outperforming expectations in their second-quarter financial results, exceeding projected earnings.
• Additionally, analysts raised their forecasts for EW following the strong Q2 results, further boosting investor confidence.
• The positive market response to the company's strong performance and positive outlook led to an increase in the stock price.

25.06.2025 - EW Stock was up 6.6%

• Q2 results for Edwards Lifesciences (EW) are believed to have surpassed expectations from analysts.
• The company's strong performance in key metrics may have boosted investor confidence, influencing the bullish movement.
• The robust Q2 performance could signal innovation and market responsiveness, attracting more investors and potentially increasing the stock price.

25.06.2025 - EW Stock was up 5.2%

• Edwards Lifesciences (EW) experienced a strong bullish movement today following its Q2 earnings report.
• The company reported Q2 sales of $1.53 billion, surpassing the estimated $1.49 billion, and an EPS of $0.67, higher than the expected $0.62.
• The positive results were primarily driven by strong performance in its transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT) segments.
• Analysts have increased their forecasts for EW after the robust Q2 results, with a price target also being raised to $101 on the company's growth momentum. The raised FY25 sales outlook further contributed to the bullish sentiment surrounding the stock.

28.00.2025 - EW Stock was up 3.6%

• Smart money is showing a bullish sentiment by betting big on Edwards Lifesciences options, indicating confidence in the company's future performance.
• This significant bullish activity from high-rolling investors could be driven by positive developments within the company, such as promising clinical trial results or new product launches.
• Retail traders should pay attention to this trend as it suggests a potential upward momentum in EW's stock price in the near future.
• Overall, the strong bullish movement in EW today may be attributed to the optimistic outlook and strategic positioning of institutional investors in the company.

28.00.2025 - EW Stock was up 5.0%

• Analysts predict a decrease in earnings for Edwards Lifesciences, but significant investment in the company's options indicates a positive market sentiment.
• The discrepancy between analyst forecasts and market behavior suggests investor anticipation of future growth or positive company developments.
• The rise in EW's stock price may be linked to the confidence displayed by high-stakes investors in the company's future potential, leading to increased purchasing activity and driving up the stock value.
• Investor interest in Edwards Lifesciences appears driven by a focus on long-term growth prospects and the company's market positioning, rather than short-term earnings forecasts.

27.09.2025 - EW Stock was up 5.8%

• The bullish movement in EW stock could be attributed to an investigation into potential breaches of fiduciary duties by the company's directors and officers.
• Investors may interpret this investigation as a sign of accountability and transparency within the company, leading to increased confidence in EW's corporate governance practices.
• This news might have reassured shareholders and attracted new investors, contributing to the positive market movement of EW stock today.

12.01.2025 - EW Stock was up 6.6%

• The company reported strong Q4 sales growth, surpassing consensus estimates and showing a 9% increase year-over-year.
• TMTT sales surged by 77% in 2023, driven by the adoption of PASCAL and EVOQUE, significantly contributing to the positive overall performance.
• TAVR sales performed robustly, reaching $1.04B in Q4 with a 5.3% increase year-over-year, additionally boosting the stock's positive movement.
• Analysts remain confident in Edwards Lifesciences' long-term prospects, which is evident in the positive market sentiment and today's bullish stock movement.

01.09.2025 - EW Stock was down 3.7%

• The bearish movement in Edwards Lifesciences stock today could be attributed to:
• Profit-taking by investors after a prolonged period of outperformance in the market.
• Concerns about potential competition or regulatory challenges in the medical technology sector.
• Overall market sentiment affecting healthcare stocks, leading to a broader sell-off in the industry.
• Technical factors triggering a short-term downward trend in the stock price.